FDA approves Chinese lymphoma treatment

0 Comment(s)Print E-mail chinadaily.com.cn, November 15, 2019
Adjust font size:

The United States Food and Drug Administration announced on Thursday it would grant accelerated approval to Chinese biomedicine company BeiGene Ltd's Brukinsa (zanubrutinib) capsules, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

That marks the first US FDA approval for a cancer therapy independently developed by a Chinese drug company.

The accelerated approval is based on overall response rate, or how many patients experience a complete or partial shrinkage of their tumors after treatment.

Mantle cell lymphoma, or MCL, is a rare, aggressive form of non-Hodgkin's lymphoma, which is a cancer developing from lymphocytes, a type of white blood cell. It usually responds well to initial treatment but eventually returns or stops responding, and cancer cells continue to grow.

In the US, MCL represents 3 to 10 percent of all non-Hodgkin's lymphoma. By the time it is diagnosed, MCL has usually spread to the lymph nodes, bone marrow and other organs. In relapsed lymphoma, the disease reappears or grows again after a period of remission, while in refractory lymphoma, the disease does not respond to treatment or responds only briefly,according to FDA's press announcement.

A single-arm clinical trial of Brukinsa included 86 patients with MCL who received at least one prior treatment. In the trial, 84 percent of patients had tumor shrinkage with a median duration of response (time between the initial response to therapy and subsequent disease progression or relapse) of 19.5 months.

The trial was supported by an additional single-arm trial that included 32 patients, in which 84 percent of patients had tumor shrinkage with a median duration of response of 18.5 months.

John V. Oyler, chairman, co-founder and CEO of BeiGene, said in a press release as the company continues to evaluate Brukinsa's potential in other hematologic cancers, it hopes the FDA approval is the first of many for the therapy.

Since Brukinsa was granted accelerated approval, which enables the FDA to approve drugs for serious conditions to fill an unmet medical need based on a result that is reasonably likely to predict a clinical benefit to patients, further clinical trials may be required to verify and describe Brukinsa's clinical benefit, according to the FDA.

Follow China.org.cn on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:   
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from China.org.cnMobileRSSNewsletter
主站蜘蛛池模板: 亚洲av午夜成人片| 伦理eeuss| 国产精品三级视频| 国产高清在线a视频大全| www五月婷婷| 成av免费大片黄在线观看| 久久亚洲欧美综合激情一区| 极品性放荡的校花小说| 亚洲欧美精品中文字幕| 男男性彩漫漫画无遮挡| 台湾佬中文娱乐网在线更新| 视频一区二区精品的福利| 国产成人免费手机在线观看视频 | 柳岩aa一一级毛片| 亚洲国产精品一区二区九九| 欧美高清xxxx做受3d| 亚洲黄色片一级| 男人边摸边吃奶边做下面| 公和我在厨房好爽中文字幕| 美女扒开腿让男人桶免费看| 国产一区高清视频| 豪妇荡乳1一5白玉兰| 国产免费一区二区三区在线观看 | avtt在线观看| 女人国产香蕉久久精品| 一卡二卡三卡四卡在线| 成人午夜兔费观看网站| 中文字幕亚洲精品资源网| 护士好爽好深好多水| 久久99精品国产麻豆不卡| 日本边添边摸边做边爱的视频| 亚洲AV无码一区二区三区网站| 欧洲成人r片在线观看| 亚洲一级黄色大片| 欧洲熟妇色xxxx欧美老妇多毛网站| 亚洲一区二区三区播放在线 | 2022国产成人福利精品视频| 国产精品成人99久久久久| 4480新热播影院| 国产精品无码免费视频二三区 | 日本欧美视频在线观看|